Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development

This study looked at the plasma levels of osteopontin (OPN) in 492 people with MS, in order to evaluate its potential as a biomarker for disease activity and/or disease subtype using ELISA. OPN is a proinflammatory cytokine involved in inflammation and immunity.

When compared to controls, OPN levels were higher in RRMS and SPMS patients. The researchers did not find any significant association between OPN levels and disease activity. One third of people with MS with high OPN levels had concurrent disorders which may cause increased OPN expression. Therefore, this study does not support the use of plasma OPN levels as a biomarker for disease activity in a heterogenous clinical setting. However, this does not exclude the potential role of OPN in the cerebrospinal fluid.

Authors: Kivisäkk P, Healy BC
Source: Mult Scler. 2013 Sep 4. [Epub ahead of print]

Read the abstract 


Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial